Literature DB >> 8453945

Neuroprotective effect of felbamate after kainic acid-induced status epilepticus.

A Chronopoulos1, C Stafstrom, S Thurber, P Hyde, M Mikati, G L Holmes.   

Abstract

Felbamate (FBM), a newly developed antiepileptic drug (AED), was previously shown to offer some neuroprotective effects against hypoxic injury in both in vivo and in vitro studies. We administered FBM (100 or 300 mg/kg) to 30-day-old rats 1 h after they received a convulsant dosage of kainic acid (KA). Animals were then tested at age 80 days in the water maze, open field, and handling tests. Seizure latency was then tested by flurothyl inhalation. Animals that received 300 mg/kg FBM performed better in all three tests and had longer latencies to flurothyl-induced seizures than did animals that received vehicle. This study suggests that FBM may have some neuroprotective effects after KA-induced status epilepticus (SE).

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8453945     DOI: 10.1111/j.1528-1157.1993.tb02422.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  4 in total

1.  Cognitive Adverse Effects of Antiepileptic Drugs : Incidence, Mechanisms and Therapeutic Implications.

Authors:  R Kälviäinen; M Äikiä; P J Riekkinen
Journal:  CNS Drugs       Date:  1996-05       Impact factor: 5.749

2.  Electrophysiological actions of felbamate on rat striatal neurones.

Authors:  A Pisani; A Stefani; A Siniscalchi; N B Mercuri; G Bernardi; P Calabresi
Journal:  Br J Pharmacol       Date:  1995-10       Impact factor: 8.739

Review 3.  Newer antiepileptic drugs. Towards an improved risk-benefit ratio.

Authors:  P N Patsalos; J W Sander
Journal:  Drug Saf       Date:  1994-07       Impact factor: 5.606

4.  Felbamate as an oral add-on therapy in six dogs with presumptive idiopathic epilepsy and generalized seizures resistant to drug therapy.

Authors:  Curtis Wells Dewey; Mark Rishniw; Kasie Sakovitch
Journal:  Open Vet J       Date:  2022-07-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.